AKT1 and Insulin resistance: Conversely, elevated insulin levels resulting from hyperglycemia or insulin resistance may activate growth-promoting pathways such as PI3K/AKT (Varma et al., 2005), thereby counteracting metformin’s inhibitory effects on cancer cells.